Health ❯ Medical Research ❯ Gene Therapy ❯ Neurological Disorders
The one-time, neurosurgically delivered treatment showed three-year benefits in a 29-patient Phase 1/2 study, with full data to be presented next month and an FDA filing targeted for early 2026.
